Meseclazone

Meseclazone (W2395; NSC297623) exhibits inhibitory potency of secondary phase ADP aggregation. Meseclazone possesses anti-inflammatory, analgesic and antipyretic activity.

Product Specifications

CAS Number

[29053-27-8]

Product Name Alternative

W2395; NSC297623

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

P2Y Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/NSC297623.html

Solubility

10 mM in DMSO

Smiles

O=C1N(OC(C)C2)C2OC3=CC=C(Cl)C=C13

Molecular Formula

C11H10ClNO3

Molecular Weight

239.66

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Diamantis W, et al. Meseclazone, 5-chlorosalicylic acid and acetylsalicylic acid. Comparison of their effects on in vitro and ex vivo platelet aggregation. Thromb Haemost. 1978 Aug 31;40 (1) :24-36.|[2]Diamantis W, et al. Antagonism by meseclazone and other nonsteroidal anti-inflammatory drugs of bradykinin-induced bronchospasm. Pharmacology. 1982;24 (4) :243-7.